|
|
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
|
|
|
T2 Biosystems Regains Compliance with Nasdaq Listing Requirements
|
|
|
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference
|
|
|
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
|
|
|
T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates
|
|
|
T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii
|
|
|
T2 Biosystems Announces Reverse Stock Split Effective Today
|
|
|
T2 Biosystems Reports Granting of Inducement Award
|
|
|
T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023
|
|
|
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel
|
